Scotland says yes to BI/Lilly's Tradjenta and Lilly's Bydureon
This article was originally published in Scrip
Executive Summary
Scotland's health technology appraisal body, the Scottish Medicines Consortium (SMC) has said a partial yes to two anti-diabetics drugs, Boehringer Ingelheim/Lilly's DPP-4 inhibitor Tradjenta (linagliptin) and Lilly's GLP1-agonist Bydureon (prolonged-release exenatide). Meanwhile it has given Roche's anticancer Tarceva (erlotinob) a full green light for some lung cancer patients.